RGNX250117C2500
- 0.00
- 0.000.00%
Regenxbio Newsroom
Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $30
RegenXBio (RGNX) Gets a Buy From RBC Capital
Regenxbio and Nippon Shinyaku Forge $810m Gene Therapy Deal
Regenxbio Analyst Ratings
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $36
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Illumina (ILMN) and RegenXBio (RGNX)
Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $22
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
Strategic Partnerships and Promising Pipeline Drive Buy Rating for RegenXBio
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday
Little Excitement Around REGENXBIO Inc.'s (NASDAQ:RGNX) Revenues
RegenXBio Shares Are Trading Higher After the Company Announced a Partnership With Nippon Shinyaku in a $810 Million Deal.
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $22
Market-Moving News for January 14th
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Bank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
REGENXBIO Partners With Nippon Shinyaku in $810M Deal for Hunter and Hurler Syndrome Therapies
Express News | Regenxbio Inc - Retains Rights to Rgx-121 Priority Review Voucher